Status:
COMPLETED
Hearing Instruments in Alzheimer's Disease
Lead Sponsor:
Phonak AG, Switzerland
Collaborating Sponsors:
University of Toronto
Baycrest Centre for Geriatric Care
Conditions:
Alzheimer Disease
Hearing Loss
Eligibility:
All Genders
60+ years
Brief Summary
There is a strong connection between hearing loss and cognitive impairment, particularly dementia, in old age. Worldwide, dementia affects approximately 5% of persons over the age of 65 years. Hearing...
Detailed Description
Currently, five percent of individuals over the age of 65 suffer from Alzheimer's disease (AD) or a related dementia. Given that hearing loss affects approximately one third of individuals over the ag...
Eligibility Criteria
Inclusion
- Referred to the Audiology department by a physician with a confirmed diagnosis of Alzheimer's disease (or no diagnosis of AD if a normal cognition participant)
- Pure-tone threshold at 3 kHz in excess of 35 dB HL in the worse ear
- 60 years of age or older
- Able to read and communicate well in English
- Allow the researchers access to their medication list throughout the study to assess any changes in medications
- Willing to use one or more hearing aid(s) on a regular basis
- Has a caregiver who…
- Is a family member
- Is over the age of 18
- Is able to read and communicate well in English.
- Accompanies participant to Baycrest for all necessary appointments
- Provides qualitative and quantitative assessments of the participant's everyday behaviours and functioning
- Is willing to learn and support the participant in using hearing aid(s), provide information on their own well-being and communication function
- If they currently use one or more hearing aid(s), have acquired said aid(s) at least one year prior and are using it/them in a stable fashion.
Exclusion
- Suffered a traumatic brain injury or stroke within the past five years
- Has a history of untreated psychiatric illness
- Has an uncorrected deficit in visual acuity or an untreated visual medical issue (e.g., glaucoma, macular degeneration, diabetic retinopathy)
- Suffers from a neurological disorder (e.g., multiple sclerosis, epilepsy)
- Has any untreated medical conditions that could jeopardize participation in the study
- Has been taking medication for their cognitive impairment (e.g., cholinesterase inhibitor, NMDA receptor antagonists) for less than one month.
- Has a caregiver who…
- Is not cognitively stable (e.g., has been diagnosed with mild cognitive impairment or dementia)
- Has a terminal medical or untreated psychiatric conditions that could jeopardize their participation in the study.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2017
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT02294513
Start Date
October 1 2014
End Date
February 1 2017
Last Update
April 11 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baycrest Center of Geriatric Care
Toronto, Ontario, Canada, M6A 2E1